EUCTR2009-013198-16-IT进行中（未招募）不适用
Acute Myocardial Infarction and endothelial function. Assessment with a non invasive ultrasonographic computerized method during oral vitamin C supplementation. - FIMAVIC
IVERSITA` DEGLI STUDI DI PARMA0 个研究点开始时间: 2009年11月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Patients of either gender, age> 25 years and < 60 -With a new non fatal AMI (STEMI NSTEMI) -Patients gave their informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-patients suffered from cardiogenic shock, hypotension ( systolic blood pressure less than 100 mmHg for at least 30 minutes, pulmonary oedema, mayor arrhythmias, -without major systemic illnesses -renal insufficiency (GFR < 30 ml/min) and -pregnancy or oral contraceptives -Alcoholism
研究者
相似试验
尚未招募
不适用
Assessment of myocardial function, endothelial function and perFUSION in early and advanced disease stages of Hypertrophic CardioMyopathy: FUSION-HCMEnlarged heart muscle disease1002859310007510NL-OMON56339Amsterdam UMC100
已完成
不适用
The relation of endothelial dysfunction with cardiovascular events after acute coronary syndrome.Acute coronary syndromeJPRN-UMIN000044517Yokohama City University Medical Center688
招募中
不适用
Microvascular Dysfunction in Acute Myocardial Infarction and its Relation to Outcome.No reflow phenomenon after acute myocardial infarction. Myocardial perfusion after heart attack.10082206NL-OMON35137Catharina-ziekenhuis25
已完成
不适用
A clinical study of endothelial function and cardiac function and cardio-renal biomarkers in chronic kidney diseasechronic kidney diseaseJPRN-UMIN000003614Okayama university Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences300
进行中（未招募）
1 期
Acute Myocardial infarction Upbound to percutaneous coronary intervention, immediately (STEMI) or in the Next three Days (NSTEMI), and randomized to Subcutaneous Evolocumab or Normal strategies to reach guidelines LDL objectives in the real-world- The AMUNDSEN-real studyEUCTR2021-000573-80-FRAPHP DRCI